In this issue of Px Wire, we take a hard look at a host of major milestones coming up toward ambitious global targets for ending the epidemic. We also include detailed infographics on showing the status of oral PrEP rollout in the countries where trial sites are located, explaining the demographics of Africa’s “youth bulge” and its implications for the global response and more.
Px Wire January-March 2018, Vol. 11, No. 1
What’s the State of the Field? AVAC Report 2017
On the eve of World AIDS Day 2017, AVAC published its annual report on the state of the field. AVAC Report 2017: Mixed Messages and How to Untangle Them is a must-read for anyone tracking the progress of HIV prevention around the world. In this month’s episode of Px Pulse, AVAC’s Director of Strategy & Content Emily Bass shares highlights from the report and calls for action on the unfinished work of scaling up prevention.
AVAC Report 2017: Mixed messages and how to untangle them
AVAC is excited to share our annual “state of the field” report on biomedical prevention research and implementation. AVAC Report 2017: Mixed Messages and How to Untangle Them is straight talk about today’s complex context for HIV prevention. Read this report if you’ve wondered that there’s more rhetorical support than ever for HIV prevention but no more money? How can the world be “on the path to epidemic control” while human rights are trampled in many places, and rates of HIV diagnoses climb in others? How can scientists be so sure they know what women want, without doing research to find out?
For more from the report, including a link to all its graphics, visit avac.org/report2017.
Px Wire October-December 2017, Vol. 10, No. 4
In Px Wire, we preview part of the AVAC Report 2017, which includes a set of recommendations and priorities that keep funding and research crossing-cutting, strategic and responsive to people’s real-world needs. Check out the infographic, which provides a visual history of the DAIDS Networks and a look at what’s proposed for the next funding cycle.
Px Wire July-September 2017, Vol. 10, No. 3
This issue of AVAC’s quarterly newsletter, Px Wire, is now available. Check it out for a deep dive into the data that suggest men who have sex with men may be able protected by oral PrEP, even if they don’t dose every day—and for the reasons why these data do not apply to women. You’ll also find out why messages about global AIDS are on our mind—and what we’d change about the current global conversation.
HIV Prevention Research & Development Investments, 2000–2016: Investment priorities to fund innovation in a challenging global health landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2016, funding for HIV prevention R&D decreased by US$35 million from the previous year to a total of US$1.17 billion. This marks the lowest recorded annual investment in more than a decade. While investments toward research in preventive vaccines, PrEP and medical male circumcision increased in 2016, funding for microbicides, treatment as prevention, female condoms and prevention of vertical transmission decreased.
Global Investment in HIV Cure Research and Development in 2016: Funding for a cure remains a priority
Don’t miss this report looking at investment in cure research in 2016. It’s part of the annual report on investment in research and development that AVAC produces as a member of the Resource Tracking for HIV Prevention Research & Development Working Group.
Advocacy in Uncertain Times: A call to action
AVAC’s report for HIV Vaccine Awareness Day on the state of the HIV vaccine research and development field, including key priorities for advancing research and sustaining support.
Px Wire April-June 2017, Vol. 10, No. 2
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, offers an advocate’s guide to some new types of biomedical prevention trial designs. You’ll find a summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
What Is Up With DMPA And “Grades” For Family Planning?
AVAC’s sheet on the hormonal contraceptive known as Depo-Provera (DMPA) and the WHO grading system for contraceptives explains key issues in plain language. Research findings have raised questions about the safety and effectiveness of DMPA for women who face a high risk of HIV. WHO evaluates the safety and efficacy of contraceptive methods.